Vera Therapeutics (VERA) Stock Forecast & Price Target

Vera Therapeutics is supported by a materially de-risked regulatory path after the FDA’s July 7 accelerated approval of Trutakna, which made it the first approved agent targeting both BAFF and APRIL in IgAN and validates the platform. The company’s outlook is further strengthened by the revised, earlier ORIGIN 3 eGFR analysis, now expected in 3Q26 instead of 2027, with management still guiding to a 4Q26 sBLA submission if the data are positive. Relative to Otsuka’s Voyxact, Vera’s competitive positioning remains credible, and earlier full approval could improve formulary access and adoption as payers and nephrologists may prefer approval backed by eGFR data.

Vera Therapeutics is facing a negative outlook because atacicept must overcome a high competitive bar after Voyxact’s strong 24-month eGFR data, which appears to compress differentiation in IgAN and shifts competition toward dosing convenience and commercial execution. The company also remains financially strained, reporting no revenue in 2Q26, a net loss of $1.52 per share, and projecting only $16M of 2026 revenue against a $6.52 per diluted share loss, while still likely needing additional funding to fully develop and commercialize the drug. Regulatory risk adds further pressure, since accelerated approval strategies may require more data or longer studies, and weaker-than-expected product labels could limit market traction even with approximately $499M in cash, cash equivalents, and marketable securities at the end of 2Q26.